TGF-Î²: An emerging player in drug resistance

Cell Cycle

12, 2960-2968

DOI: 10.4161/cc.26034

Citation Report

#	Article	IF	Citations
1	Molecular Pathways of Colorectal Carcinogenesis are Promising Mistery?. Journal of Carcinogenesis & Mutagenesis, 2014, S10, .	0.3	1
2	A crucial role for the phosphorylation of STRAP at Ser¹⁸⁸by MPK38 in STRAP-dependent cell death through ASK1, TGF-Î², p53, and PI3K/PDK1 signaling pathways. Cell Cycle, 2014, 13, 3357-3374.	1.3	21
3	Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle, 2014, 13, 3808-3817.	1.3	16
4	Finding effective cancer therapies through loss of function genetic screens. Current Opinion in Genetics and Development, 2014, 24, 23-29.	1.5	21
5	Drug resistance to targeted therapies: DÃ©jÃ vu all over again. Molecular Oncology, 2014, 8, 1067-1083.	2.1	187
6	Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 335-344.	1.0	17
7	The TGF-Î² pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells. Oncotarget, 2016, 7, 22077-22091.	0.8	49
8	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget, 2016, 7, 20810-20824.	0.8	73
9	Regulation of Natural Killer Cell Function by STAT3. Frontiers in Immunology, 2016, 7, 128.	2.2	64
10	TGFÎ² signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Molecular Medicine, 2016, 8, 745-760.	3.3	119
11	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell, 2016, 165, 317-330.	13.5	70
12	Ly6E/K Signaling to TGFÎ² Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Research, 2016, 76, 3376-3386.	0.4	80
13	Crosstalk between TGF-Î² signaling and miRNAs in breast cancer metastasis. Tumor Biology, 2016, 37, 10011-10019.	0.8	38
14	Long non-coding RNA regulation of epithelialâ€“mesenchymal transition in cancer metastasis. Cell Death and Disease, 2016, 7, e2254-e2254.	2.7	117
15	Epithelialâ€“mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer, 2016, 19, 53-62.	2.7	52
16	Targeting TGF-Î² Signaling in Cancer. Trends in Cancer, 2017, 3, 56-71.	3.8	697
17	Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-Î²1-dependent activation of Smad/ERK signaling. Cell Death and Disease, 2017, 8, e2885-e2885.	2.7	35
18	Node-based learning of differential networks from multi-platform gene expression data. Methods, 2017, 129, 41-49.	1.9	16

#	Article	IF	Citations
19	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Annals of Oncology, 2017, 28, 1032-1035.	0.6	43
20	A83-01 inhibits TGF-Î²-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Research and Treatment, 2017, 163, 449-460.	1.1	39
21	EZH2 is involved in silencing of WNT5A during epithelialâ€“mesenchymal transition of colon cancer cell line. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2211-2219.	1.2	15
22	A molecular signature for anastasis, recovery from the brink of apoptotic cell death. Journal of Cell Biology, 2017, 216, 3355-3368.	2.3	103
23	Hedyotis diffusa Willd suppresses metastasis in 5-fluorouracil-resistant colorectal cancer cells by regulating the TGF-Î² signaling pathway. Molecular Medicine Reports, 2017, 16, 7752-7758.	1.1	24
24	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. OncoTargets and Therapy, 2017, Volume 10, 5491-5524.	1.0	56
25	c-Jun/AP-1 overexpression reprograms ERÎ± signaling related to tamoxifen response in ERÎ±-positive breast cancer. Oncogene, 2018, 37, 2586-2600.	2.6	37
27	Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. Journal of Controlled Release, 2018, 275, 67-77.	4.8	50
28	The Dual Role of Bone Morphogenetic Proteins in Cancer. Molecular Therapy - Oncolytics, 2018, 8, 1-13.	2.0	149
29	TGFÎ² pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130.		85
30	Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. International Journal of Molecular Sciences, 2018, 19, 3014.	1.8	12
31	A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. Scientific Reports, 2018, 8, 14091.	1.6	19
32	Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-Î² pathway. Theranostics, 2018, 8, 4733-4749.	4.6	56
33	Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-Îºb/survivin signaling pathway. Biomedicine and Pharmacotherapy, 2018, 104, 729-737.	2.5	15
34	The Dynamic Roles of TGF-Î² Signalling in EBV-Associated Cancers. Cancers, 2018, 10, 247.	1.7	23
35	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 2018, 10, .	5.8	32
36	Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. International Journal of Biochemistry and Cell Biology, 2018, 102, 128-137.	1.2	19
37	Cell signaling and cancer: a mechanistic insight into drug resistance. Molecular Biology Reports, 2019, 46, 5645-5659.	1.0	63

#	Article	IF	Citations
38	Recent Progress on Circular RNA Research in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1108.	1.3	57
39	Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 173, 169-175.	1.4	4
40	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology, 2019, 21, 778-790.	4.6	24
41	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. BMC Cancer, 2019, 19, 421.	1.1	2
42	MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 427-439.	1.1	20
43	Screening candidate microRNAâ€mRNA network for predicting the response to chemoresistance in osteosarcoma by bioinformatics analysis. Journal of Cellular Biochemistry, 2019, 120, 16798-16810.	1.2	12
44	Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy. Science China Materials, 2019, 62, 873-884.	3.5	3
45	Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer. Cancers, 2019, 11, 293.	1.7	32
46	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	1.7	71
47	High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype. Disease Markers, 2019, 2019, 1-9.	0.6	6
48	Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nature Communications, 2019, 10, 1693.	5.8	119
49	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine, 2019, 8, 205.	1.0	17
50	TGF-Î² induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle, 2019, 18, 3589-3602.	1.3	48
51	Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics, 2019, 11, 35-51.	1.0	84
52	Role of the transforming growth factorâ€Î² signaling pathway in the pathogenesis of colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 8899-8907.	1.2	35
53	CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5pâ€"XIAP axis. Experimental Hematology, 2019, 70, 42-54.e3.	0.2	112
54	Activated Wnt/Î²-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. Life Sciences, 2020, 254, 116816.	2.0	10
55	TGFÎ²R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Reports, 2020, 33, 108221.	2.9	18

#	Article	IF	Citations
56	TGF-Î² causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 2020, 10, 7656-7670.	4.6	34
57	Obg-like ATPase 1 inhibited oral carcinoma cell metastasis through TGFÎ²/SMAD2 axis in vitro. BMC Molecular and Cell Biology, 2020, 21, 65.	1.0	3
58	miR-552: an important post-transcriptional regulator that affects human cancer. Journal of Cancer, 2020, 11, 6226-6233.	1.2	13
59	Effects of different levels of TGF-Î² expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma. Journal of Bone Oncology, 2020, 23, 100299.	1.0	7
60	Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes. OMICS A Journal of Integrative Biology, 2020, 24, 340-351.	1.0	18
61	Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. OMICS A Journal of Integrative Biology, 2020, 24, 314-339.	1.0	35
62	Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-Î² signaling and radioiodine resistance. Journal of Biological Chemistry, 2020, 295, 10726-10740.	1.6	9
63	Long non-coding RNA in bladder cancer. Clinica Chimica Acta, 2020, 503, 113-121.	0.5	31
64	The prognostic role of soluble transforming growth factorâ€Î² and its correlation with soluble programmed deathâ€ligand 1 in biliary tract cancer. Liver International, 2021, 41, 388-395.	1.9	4
65	Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development. OMICS A Journal of Integrative Biology, 2021, 25, 81-92.	1.0	17
66	Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy. Journal of Controlled Release, 2021, 329, 1023-1036.	4.8	18
68	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 641469.	1.8	76
69	Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-Î² Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p. Cell Biochemistry and Biophysics, 2021, 79, 757-767.	0.9	9
71	GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment. Biology, 2021, 10, 836.	1.3	9
72	Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8. Biological Chemistry, 2021, 402, 1247-1256.	1.2	5
74	Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-Î² mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicology in Vitro, 2021, 74, 105152.	1.1	21
75	Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy. ACS Nano, 2021, 15, 14149-14161.	7.3	34
76	TGF-Î²-Induced TMEPAI Promotes Epithelialâ€"Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration. Breast Cancer: Targets and Therapy, 2021, Volume 13, 529-538.	1.0	2

#	Article	IF	Citations
77	Cancerâ€associated fibroblasts mediated chemoresistance by a FOXO1/TGFÎ²1 signaling loop in esophageal squamous cell carcinoma. Molecular Carcinogenesis, 2017, 56, 1150-1163.	1.3	67
78	Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British Journal of Cancer, 2018, 118, 106-116.	2.9	24
80	5â€Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Science, 2020, 111, 3142-3154.	1.7	230
81	TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex. Oncotarget, 2017, 8, 106565-106576.	0.8	8
82	Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 141-160.	0.9	388
83	Exploiting Canonical TGFÎ² Signaling in Cancer Treatment. Molecular Cancer Therapeutics, 2022, 21, 16-24.	1.9	10
85	Dual genome-wide CRISPR knockout and CRISPR activation screens identifyÂmechanisms that regulate the resistance to multiple ATR inhibitors. PLoS Genetics, 2020, 16, e1009176.	1.5	17
86	TGF-Î² protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1Î± dependent manner. BMC Cancer, 2021, 21, 1200.	1.1	8
87	Regulatory role of the transforming growth factor-Î² signaling pathway in the drug resistance of gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2021, 13, 1648-1667.	0.8	4
88	TGF-Î² Signaling and Resistance to Cancer Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 786728.	1.8	66
89	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. Drug Resistance Updates, 2022, 60, 100811.	6.5	13
90	Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors. ACS Omega, 2022, 7, 3293-3311.	1.6	3
91	Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers. Technology in Cancer Research and Treatment, 2022, 21, 153303382110689.	0.8	12
93	The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-Î² and PD-L1 Pathways. Frontiers in Oncology, 2022, 12, 814169.	1.3	8
94	Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1â€"Dependent TGFÎ²1 Activation and Suppressing Immunity in Bone Marrow. Molecular Cancer Therapeutics, 2022, 21, 347-358.	1.9	6
95	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. Cancers, 2022, 14, 2176.	1.7	5
96	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 2022, 14, 2928.	1.7	34
97	Estimating intraclonal heterogeneity and subpopulation changes from bulk expression profiles in CMap. Life Science Alliance, 2022, 5, e202101299.	1.3	2

#	Article	IF	Citations
98	Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). International Journal of Oncology, 2022, 61, .	1.4	3
99	Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state. ELife, 0, 11, .	2.8	3
100	Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. Cell Death and Disease, 2022, 13, .	2.7	4
101	Importance of TGFÎ² in Cancer and Nematode Infection and Their Interactionâ€"Opinion. Biomolecules, 2022, 12, 1572.	1.8	4
102	Mechanism and function of miR-140 in human cancers: A review and in silico study. Pathology Research and Practice, 2023, 241, 154265.	1.0	3
103	Epithelial TGFÎ² engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature Communications, 2022, 13, .	5.8	2
104	The ceRNA network regulates epithelial-mesenchymal transition in colorectal cancer. Heliyon, 2023, 9, e14143.	1.4	7
105	High expression of LY6E is an independent prognostic factor of colorectal cancer patients. Oncology Reports, 2023, 49, .	1.2	1
106	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. World Journal of Gastroenterology, 0, 29, 1911-1941.	1.4	0
107	Evaluation of BMP-2 as a Differentiating and Radiosensitizing Agent for Colorectal Cancer Stem Cells. Current Stem Cell Research and Therapy, 2024, 19, 83-93.	0.6	1
108	TGF-Î² mediated drug resistance in solid cancer. Cytokine and Growth Factor Reviews, 2023, 71-72, 54-65.	3.2	9